Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Biochem Cell Biol ; 80: 173-178, 2016 11.
Article in English | MEDLINE | ID: mdl-27720933

ABSTRACT

Secondary metastases are the leading cause of mortality in patients with breast cancer. Cytochrome P450 (CYP) 2J2 (CYP2J2) is upregulated in many human tumors and generates epoxyeicosanoids from arachidonic acid that promote tumorigenesis and metastasis, but at present there is little information on the genes that mediate these actions. In this study MDA-MB-468 breast cancer cells were stably transfected with CYP2J2 (MDA-2J2 cells) and Affymetrix microarray profiling was undertaken. We identified 182 genes that were differentially expressed in MDA-2J2 cells relative to control (MDA-CTL) cells (log[fold of control] ≥2). From gene ontology pathway analysis bone morphogenetic protein (BMP) receptor 1B (BMPR1B) emerged as an important upregulated gene in MDA-2J2 cells. Addition of the BMPR1B ligand BMP2 stimulated the migration of MDA-2J2 cells, but not MDA-CTL cells, from 3D-matrigel droplets. Migration of MDA-2J2 cells was prevented by the BMPR antagonist dorsomorphin. These findings indicate that over-expression of CYP2J2 in MDA-MB-468-derived breast cancer cells activates BMPR1B expression that may contribute to increased migration. Targeting BMPR1B may be a novel approach to inhibit the metastatic activity of breast cancers that contain high levels of CYP2J2.


Subject(s)
Bone Morphogenetic Protein Receptors, Type I/genetics , Cell Movement/genetics , Cytochrome P-450 Enzyme System/genetics , Transcriptional Activation , Triple Negative Breast Neoplasms/pathology , Carcinogenesis/genetics , Cell Line, Tumor , Cytochrome P-450 CYP2J2 , Gene Expression , Gene Ontology , Humans , Neoplasm Metastasis , Up-Regulation/genetics
2.
Pharmaceutics ; 5(1): 36-68, 2012 Dec 21.
Article in English | MEDLINE | ID: mdl-24300396

ABSTRACT

Intravenous nanoemulsions have been on the market for parenteral nutrition since the 1950s; meanwhile, they have also been used successfully for IV drug delivery. To be well tolerable, the emulsions should avoid uptake by the MPS cells of the body; for drug delivery, they should be target-specific. The organ distribution is determined by the proteins adsorbing them after injection from the blood (protein adsorption pattern), typically analyzed by two-dimensional polyacrylamide gel electrophoresis, 2-D PAGE. The article reviews the 2-D PAGE method, the analytical problems to be faced and the knowledge available on how the composition of emulsions affects the protein adsorption patterns, e.g., the composition of the oil phase, stabilizer layer and drug incorporation into the interface or oil core. Data were re-evaluated and compared, and the implications for the in vivo distribution are discussed. Major results are that the interfacial composition of the stabilizer layer is the main determining factor and that this composition can be modulated by simple processes. Drug incorporation affects the pattern depending on the localization of the drug (oil core versus interface). The data situation regarding in vivo effects is very limited; mainly, it has to be referred to in the in vivo data of polymeric nanoparticles. As a conclusion, determination of the protein adsorption patterns can accelerate IV nanoemulsion formulation development regarding optimized organ distribution and related pharmacokinetics.

3.
Macromol Biosci ; 11(7): 897-904, 2011 Jul 07.
Article in English | MEDLINE | ID: mdl-21472988

ABSTRACT

The goal of this study was to investigate the suitability of poly(ethylene carbonate) (PEC) nanoparticles as a novel drug delivery system, fulfilling the requirements for a long circulation time. Particles were obtained with a narrow size distribution and nearly neutral zeta potential. Adsorption studies with human plasma proteins revealed that PEC nanoparticles bind much less proteins in comparison to polystyrene (PS) nanoparticles. Cell experiments with fluorescently labeled PEC showed no uptake of the nanoparticles by macrophages. These novel PEC nanospheres with their unique surface properties are a promising candidate for long circulating drug delivery systems in vivo.


Subject(s)
Drug Carriers/chemistry , Nanospheres/chemistry , Polyethylenes/chemistry , Adsorption , Animals , Blood Proteins/metabolism , Drug Carriers/metabolism , Drug Delivery Systems , Fluorescent Dyes , Humans , Macrophages/immunology , Macrophages/metabolism , Mice , Particle Size , Polyethylenes/metabolism , Protein Binding , Surface Properties
4.
J Liposome Res ; 21(3): 245-54, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21174528

ABSTRACT

The preferential in vitro adsorption of apolipoprotein E (Apo E) onto the surface of colloidal drug carriers may be used as a strategy to evaluate the in vivo potential for such systems to transport drugs to the brain. The aim of this research was to investigate the in vitro protein adsorption patterns of didanosine-loaded nanostructured lipid carriers (DDI-NLCs), using two-dimensional polyacrylamide gel electrophoresis (2-D PAGE), in order to establish the potential for NLCs to deliver DDI to the brain. NLC formulations were manufactured using high-pressure homogenization using a lipid matrix consisting of a mixture of Precirol(®) ATO 5 and Transcutol(®) HP. The 2-D PAGE analysis revealed that NLCs in formulations stabilized using Solutol(®) HS 15 alone or with a ternary surfactant system consisting of Solutol(®) HS 15, Tween(®) 80, and Lutrol(®) F68, preferentially adsorbed proteins, such as Apo E. Particles stabilized with Tween(®) 80 and Lutrol(®) F68 did not adsorb Apo E in these studies, which could be related to the relatively large particle size and hence small surface area observed for these NLCs. These findings have revealed that DDI-loaded NLCs may have the potential to deliver DDI to the brain in vivo and, in addition, to Tween(®) 80, which has already been shown to have the ability to facilitate the targeting of colloidal drug delivery systems to the brain. Solutol(®) HS 15-stabilized nanoparticles may also achieve a similar purpose.


Subject(s)
Anti-HIV Agents/chemistry , Brain/metabolism , Didanosine/chemistry , Drug Carriers/chemistry , Drug Delivery Systems , Nanostructures/chemistry , Proteins/chemistry , Adsorption , Anti-HIV Agents/metabolism , Didanosine/metabolism , Drug Carriers/metabolism , Electrophoresis, Gel, Two-Dimensional , Humans , Lipids , Particle Size , Surface Properties , Surface-Active Agents/chemistry
5.
Nanomedicine ; 7(3): 333-40, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21094278

ABSTRACT

Nevirapine is a poorly water-soluble antiretroviral drug. Intravenous nevirapine nanosuspensions (NS) (457 ± 10 nm) were prepared by high-pressure homogenization. NS were surface modified by stabilizer adsorption, e.g., serum albumin, polysaccharide and polyethylene glycol (PEG) 1000. The NS were characterized for mean particle size, particle size distribution and polydispersity index. The targeting potential of the nonmodified and three surface-modified NS to the mononuclear phagocytic system (MPS) cells that serve as potent viral reservoirs was assessed by in vitro protein adsorption studies using two-dimensional polyacrylamide gel electrophoresis (2-D PAGE). The adsorption patterns were qualitatively identical, but showed quantitative differences. The relatively adsorbed high amounts of immunoglobulins indicate uptake by liver and spleen, observed quantitative differences (e.g., the amount of dysopsonin albumin and apolipoproteins) can modulate the organ distribution. Controlled in vitro optimization of the protein adsorption by surface modification of the nanocrystals can reduce the number of animals required for in vivo studies and accelerate development of targeted nanoparticles. FROM THE CLINICAL EDITOR: In this study, intravenous nevirapine (a poorly water-soluble antiretroviral drug) nanosuspensions were prepared by high-pressure homogenization and characterized.


Subject(s)
Acquired Immunodeficiency Syndrome/drug therapy , Blood Proteins/metabolism , Nanoparticles/chemistry , Nevirapine/therapeutic use , Adsorption/drug effects , Animals , Chemistry, Pharmaceutical , Humans , Nevirapine/pharmacokinetics , Nevirapine/pharmacology , Polyethylene Glycols/chemistry , Polysaccharides/chemistry , Radioactivity , Rats , Suspensions , Tissue Distribution/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...